Sakar Healthcare Q1 Results FY27: Net Profit at Rs 10 Cr for June 2026 Quarter

Key Takeaways

• Revenue for the June 2026 quarter came in at Rs 72 Cr, rose 38.37% year on year from Rs 52 Cr.
• Net profit stood at Rs 10 Cr on a consolidated basis.
• Gross profit was reported at Rs 14 Cr for the quarter.
• The stock traded at Rs 802.2 on 24 July 2026, down 3.07% during the session.

The Sakar Healthcare Q1 results FY27 were announced on 24 July 2026, with the pharmaceutical formulations company posting consolidated revenue of Rs 72 Cr for the quarter ended 30 June 2026. The net profit for the quarter stood at Rs 10 Cr. This article breaks down the Sakar Healthcare Q1 results FY27 in detail, covering revenue, profitability, the stock price reaction and what the numbers mean for investors tracking the counter.

Prepared by Ankit Jaiswal, Senior Research Analyst at Univest, this review of the Sakar Healthcare Q1 results FY27 relies on figures disclosed in the company’s exchange filings and result summaries for the June 2026 quarter.

Click Here – Get Free Investment Predictions

Sakar Healthcare Q1 Results FY27: Key Numbers at a Glance

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 72 Cr	Rs 52 Cr	38.37%
Gross Profit	Rs 14 Cr	Rs 7 Cr	106.16%
Net Profit	Rs 10 Cr	Rs 4 Cr	120.17%

All figures above are on a consolidated basis, as reported for the quarter ended 30 June 2026. The table places the Sakar Healthcare Q1 results FY27 in context against the same quarter of the previous financial year, which helps separate genuine operating momentum from base effects.

Revenue Performance in the June 2026 Quarter

Revenue in the Sakar Healthcare Q1 results FY27 came in at Rs 72 Cr. On a year-on-year basis, the topline rose 38.37% year on year from Rs 52 Cr. For a pharmaceutical formulations business, the revenue line is the cleanest indicator of underlying demand, and the June quarter print gives investors a fresh data point on how the operating environment is evolving.

Sakar Healthcare operates in the pharmaceutical formulations space, where quarterly revenue can be influenced by seasonality, order phasing and pricing trends. Investors should therefore look at the trajectory across multiple quarters rather than anchoring to a single print.

Sakar Healthcare Q1 Results FY27: Profitability and Margins

The company reported a consolidated net profit of Rs 10 Cr, up 120.17% from Rs 4 Cr in the same quarter last year. Gross profit for the quarter was Rs 14 Cr, a change of 106.16% compared with Rs 7 Cr in Q1 FY26.

Profitability trends in this quarter matter because they show how much of the revenue growth is flowing through to shareholders. The gap between revenue growth and profit growth, if any, points to cost pressures or mix changes that deserve attention in the management commentary.

Stock Price Reaction to the Sakar Healthcare Q1 Results FY27

On 24 July 2026, the stock traded at Rs 802.2, down 3.07% for the session. The immediate market reaction to quarterly numbers is often noisy, as prices also respond to broader market cues, sector moves and positioning ahead of the announcement.

Over the following sessions, the market will digest the Sakar Healthcare Q1 results FY27 alongside peer results and sector news. A results-day move, whether up or down, is rarely the final word on how the quarter is ultimately judged.

Talk to a SEBI Registered Investment Adviser Before You Invest

What the Sakar Healthcare Q1 Results FY27 Indicate for Investors

Taken together, the Sakar Healthcare Q1 results FY27 give investors three things to work with. First, the revenue print of Rs 72 Cr sets the base for full-year FY27 expectations. Second, the net profit of Rs 10 Cr shows where profitability currently stands on a consolidated basis. Third, the year-on-year comparisons highlight whether the business is gaining or losing momentum relative to the same period last year.

None of these numbers should be read in isolation. The quality of earnings, the composition of revenue and any one-off items disclosed in the filings all shape how the quarter should be interpreted. Reading the detailed results documents on the exchanges alongside this summary is always advisable.

Business Context for the June 2026 Quarter

Sakar Healthcare is a pharmaceutical formulations company, and its quarterly performance sits within a broader industry cycle. Demand conditions, input cost trends and the competitive landscape all feed into the reported numbers, which is why the same headline growth rate can mean very different things in different sectors. For this business, the June 2026 quarter reflects both company-specific execution and the state of the wider operating environment.

It also helps to remember that quarterly results are unaudited and subject to limited review. Any restatements, exceptional items or changes in accounting treatment disclosed in the notes to the results can materially alter how the reported profit should be read. Serious investors typically go beyond the summary card and read the full financial results, the segment disclosures and the auditor observations filed with the exchanges before forming a view on the quarter.

Key Things to Watch After the Sakar Healthcare Q1 Results FY27

• Management commentary: Guidance on demand, margins and capital allocation following the June 2026 quarter will shape how the market extrapolates these numbers into the rest of FY27.
• Sequential trends: Comparing the September 2026 quarter with this print will show whether the momentum visible in this quarter is holding, accelerating or fading.
• Sector environment: Developments in the pharmaceutical formulations space, including input costs, regulation and competitive intensity, will influence the earnings trajectory from here.
• Corporate actions: Any dividend, capex or strategic announcements accompanying the results deserve attention, as they signal management confidence in the outlook.

Download the Univest iOS App or Univest Android App to track quarterly results, live prices and research updates in one place.

Conclusion

The Sakar Healthcare Q1 results FY27 show consolidated revenue of Rs 72 Cr and a net profit of Rs 10 Cr for the quarter ended 30 June 2026. The profit delivery keeps the earnings narrative intact for now. As Ankit Jaiswal notes, investors should track the next few quarterly prints and management commentary before drawing firm conclusions, and consult a SEBI registered investment adviser before acting on these numbers.

FAQs on Sakar Healthcare Q1 Results FY27

When were the Sakar Healthcare Q1 results FY27 announced?

Ans. The Sakar Healthcare Q1 results FY27 were announced on 24 July 2026, covering the quarter ended 30 June 2026, and the figures discussed here are on a consolidated basis.

What was the revenue in the Sakar Healthcare Q1 results FY27?

Ans. Revenue for the June 2026 quarter stood at Rs 72 Cr, compared with Rs 52 Cr in the same quarter of the previous year.

What was the net profit in the Sakar Healthcare Q1 results FY27?

Ans. The company reported a net profit of Rs 10 Cr on a consolidated basis for the quarter ended 30 June 2026.

How did the stock react to the Sakar Healthcare Q1 results FY27?

Ans. Around the Sakar Healthcare Q1 results FY27, the stock traded at Rs 802.2 on 24 July 2026, down 3.07% for the session.

Were the Sakar Healthcare Q1 results FY27 consolidated or standalone?

Ans. The Sakar Healthcare Q1 results FY27 discussed in this article are on a consolidated basis, as reported in the company’s exchange filings for the June 2026 quarter.

What was the gross profit in the Sakar Healthcare Q1 results FY27?

Ans. Gross profit for the June 2026 quarter was Rs 14 Cr, against Rs 7 Cr in Q1 FY26.

What should investors watch after these results?

Ans. After these results, investors should watch management commentary, sequential trends in the September quarter, sector developments and any corporate action announcements.

Are the Sakar Healthcare Q1 results FY27 a buy signal?

Ans. Quarterly results are a data point, not a recommendation. Investors should assess valuations, earnings quality and their own risk profile, and consult a SEBI registered investment adviser before investing.